Dec 3 (Reuters) - Merck & Co said on Friday it would
supply the Canada with up to 1 million courses of molnupiravir,
its experimental oral antiviral medicine for the treatment of
The government of Canada has secured access to 500,000
courses in 2022, with options for up to 500,000 more, pending
Health Canada's approval, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy